| (USD) | Dec 2023 | Q/Q |
|---|---|---|
| Revenue | 70.5MM | -17% |
| Gross Profit | 25.2MM | -37% |
| Cost Of Revenue | 45.3MM | +1% |
| Operating Income | -151.1MM | -70717% |
| Operating Expenses | 176.3MM | - |
| Net Income | -128.1MM | - |
| R&D | 12MM | +19% |
| G&A | 31.7MM | +81% |
| Marketing | 10.5MM | +3% |
| Amortization | 2MM | +0% |
| Interest Expense | - | - |
Short Volume Ratio = Short Volume / All Volume. Source of Short Volume data comes from
FinraMoving Average Convergence/Divergence oscillator (MACD) is one of the simplest and most effective momentum indicators available.
Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. RSI oscillates between zero and 100. According to Wilder, RSI is considered overbought when above 70 and oversold when below 30.
EL MONTE, Calif., April 11, 2024--Fulgent Genetics, Inc. (NASDAQ: FLGT) ("Fulgent" or the "Company"), a technology-based company with a well-established laboratory services business and a therapeutic development business, today announced that it will release its first quarter 2024 financial results before the market opens on Friday, May 3, 2024. Management will host a conference call for the investment community the same day at 8:30 AM ET (5:30 AM PT) to discuss the results and answer questions.
Fulgent Genetics, Inc. ( NASDAQ:FLGT ) shareholders might be concerned after seeing the share price drop 25% in the...
Key Insights The projected fair value for Fulgent Genetics is US$33.29 based on 2 Stage Free Cash Flow to Equity...
Fulgent Genetics ( NASDAQ:FLGT ) Full Year 2023 Results Key Financial Results Revenue: US$289.2m (down 53% from FY...
Fulgent Genetics, Inc. (NASDAQ:FLGT) Q4 2023 Earnings Call Transcript February 28, 2024 Fulgent Genetics, Inc. beats earnings expectations. Reported EPS is $0.28, expectations were $-0.3. Fulgent Genetics, Inc. isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Greetings and welcome to […]
Q4 2023 Fulgent Genetics Inc Earnings Call
Core Business Expansion and Strong Cash Position Highlighted Amidst Overall Net Loss
EL MONTE, Calif., February 28, 2024--Fulgent Genetics, Inc. (NASDAQ: FLGT) ("Fulgent," or the "Company"), a technology-based company with a well-established laboratory services business and a therapeutic development business, today announced financial results for its fourth quarter and full year ended December 31, 2023.
EL MONTE, Calif., February 13, 2024--Fulgent Genetics, Inc. (NASDAQ: FLGT) ("Fulgent" or the "Company"), a technology-based company with a well-established clinical diagnostic business and a therapeutic development business, today announced that it will release its fourth quarter and full year 2023 financial results before the market opens on Wednesday, February 28, 2024. Management will host a conference call for the investment community the same day at 8:30 AM ET (5:30 AM PT) to discuss the re
CooperSurgical®, a global leader in fertility and women's health, and Fulgent Genetics, Inc. (NASDAQ: FLGT), a technology-based company with a well-established clinical diagnostic business and a therapeutic development business, today announced that they have partnered to offer families of Cord Blood Registry® (CBR®) exclusive newborn genetic screening panels.